Peptides Similar to Eloralintide
Compare Eloralintide with related peptides and alternatives
📌TL;DR
- •5 similar peptides identified
- •Cagrilintide: High - Both are long-acting amylin receptor agonists for obesity. Both are acylated amylin analogs with once-weekly subcutaneous dosing.
- •Petrelintide: High - Both are next-generation amylin receptor agonists developed for obesity treatment with once-weekly subcutaneous dosing.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Eloralintide (current) | - | - |
| Cagrilintide | High - Both are long-acting amylin receptor agonists for obesity. Both are acylated amylin analogs with once-weekly subcutaneous dosing. | Eloralintide is AMY1R-selective (12-fold over CTR) while cagrilintide is non-selective across amylin and calcitonin receptors. Preclinical data suggest eloralintide has better GI tolerability and quality of weight loss. |
| Petrelintide | High - Both are next-generation amylin receptor agonists developed for obesity treatment with once-weekly subcutaneous dosing. | Petrelintide (Novo Nordisk) showed 8.6% weight loss at 16 weeks in early data. Eloralintide demonstrated 20.1% at 48 weeks. Different selectivity profiles and pharmacokinetic properties. |
| Tirzepatide | Moderate - Both target obesity through peptide-based mechanisms with once-weekly SC dosing. Eli Lilly develops both. | Tirzepatide is a dual GLP-1/GIP agonist; eloralintide is an amylin agonist. Completely distinct receptor targets and mechanisms of action. Tirzepatide is FDA-approved; eloralintide is in Phase 3. |
| Semaglutide | Moderate - Both are injectable peptides for obesity with once-weekly dosing and significant weight loss efficacy. | Semaglutide is a GLP-1 receptor agonist; eloralintide acts on amylin receptors. Different mechanism of action, adverse effect profiles, and regulatory status. Semaglutide is approved; eloralintide is Phase 3. |
| Retatrutide | Low-Moderate - Both are Eli Lilly injectable peptides for obesity, but they target completely different receptor systems. | Retatrutide is a triple agonist (GLP-1/GIP/glucagon); eloralintide is an amylin agonist. Retatrutide achieved up to 24% weight loss at 48 weeks in Phase 2. Different mechanisms and adverse effect profiles. |
CagrilintideHigh - Both are long-acting amylin receptor agonists for obesity. Both are acylated amylin analogs with once-weekly subcutaneous dosing.
Differences
Eloralintide is AMY1R-selective (12-fold over CTR) while cagrilintide is non-selective across amylin and calcitonin receptors. Preclinical data suggest eloralintide has better GI tolerability and quality of weight loss.
Advantages
AMY1R selectivity may reduce nausea; preclinical evidence of preferential fat mass loss; Phase 2 shows up to 20.1% weight loss as monotherapy.
Disadvantages
Less advanced clinically than cagrilintide (which has Phase 3 data as CagriSema combination); no approved combination product pathway yet.
PetrelintideHigh - Both are next-generation amylin receptor agonists developed for obesity treatment with once-weekly subcutaneous dosing.
Differences
Petrelintide (Novo Nordisk) showed 8.6% weight loss at 16 weeks in early data. Eloralintide demonstrated 20.1% at 48 weeks. Different selectivity profiles and pharmacokinetic properties.
Advantages
More extensive published clinical data; higher peak weight loss demonstrated; published receptor selectivity characterization.
Disadvantages
Earlier in clinical development than petrelintide Phase 3 programs; direct comparison not available.
TirzepatideModerate - Both target obesity through peptide-based mechanisms with once-weekly SC dosing. Eli Lilly develops both.
Differences
Tirzepatide is a dual GLP-1/GIP agonist; eloralintide is an amylin agonist. Completely distinct receptor targets and mechanisms of action. Tirzepatide is FDA-approved; eloralintide is in Phase 3.
Advantages
Mechanistically distinct, enabling potential combination therapy. May offer weight loss through amylin pathway for non-responders to incretin therapy.
Disadvantages
Investigational vs approved; less extensive clinical data; lower peak weight loss demonstrated (20.1% vs ~22.5% for tirzepatide 15 mg).
SemaglutideModerate - Both are injectable peptides for obesity with once-weekly dosing and significant weight loss efficacy.
Differences
Semaglutide is a GLP-1 receptor agonist; eloralintide acts on amylin receptors. Different mechanism of action, adverse effect profiles, and regulatory status. Semaglutide is approved; eloralintide is Phase 3.
Advantages
Distinct mechanism offers combination potential. AMY1R selectivity may provide different tolerability profile.
Disadvantages
Investigational status; less extensive safety database; no cardiovascular outcome trial data.
RetatrutideLow-Moderate - Both are Eli Lilly injectable peptides for obesity, but they target completely different receptor systems.
Differences
Retatrutide is a triple agonist (GLP-1/GIP/glucagon); eloralintide is an amylin agonist. Retatrutide achieved up to 24% weight loss at 48 weeks in Phase 2. Different mechanisms and adverse effect profiles.
Advantages
Mechanistically complementary to incretin agonists. May be used in combination with GLP-1/GIP-based therapies.
Disadvantages
Lower peak weight loss than retatrutide in Phase 2; earlier in clinical development.
Peptides Related to Eloralintide#
Eloralintide occupies a distinct position in the anti-obesity landscape as the only AMY1R-selective amylin agonist in late-stage clinical development. Relevant comparisons include other amylin-based therapies targeting the same pathway and incretin-based therapies that represent the current standard of care.
Amylin Receptor Agonists#
Cagrilintide (Novo Nordisk)#
Cagrilintide is the most direct competitor to eloralintide. It is a long-acting amylin analog developed by Novo Nordisk, primarily as the amylin component of CagriSema (cagrilintide + semaglutide combination).
Key differences: Cagrilintide activates amylin and calcitonin receptors non-selectively, whereas eloralintide is 12-fold selective for AMY1R over CTR. In preclinical head-to-head comparisons, eloralintide induced less conditioned taste avoidance (a nausea proxy) and produced preferential fat mass loss with less lean mass depletion.
Clinical context: Cagrilintide monotherapy (2.4 mg weekly) achieved 11.5% weight loss at 68 weeks in Phase 3. Eloralintide 9 mg achieved 20.1% at 48 weeks in Phase 2. Direct comparison is not possible due to different trial designs, populations, and durations.
Petrelintide (Novo Nordisk)#
Petrelintide is another next-generation amylin analog from Novo Nordisk. Early clinical data showed 8.6% weight loss at 16 weeks. It is being developed for both monotherapy and combination use but has less published characterization than eloralintide.
Incretin-Based Therapies#
Tirzepatide (Eli Lilly)#
Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). In the SURMOUNT-1 trial, tirzepatide 15 mg achieved approximately 22.5% weight loss at 72 weeks.
Complementary mechanism: Eli Lilly is developing eloralintide as a potential combination partner for tirzepatide. Because amylin and GLP-1/GIP act through distinct receptor pathways, combination therapy could produce additive or synergistic effects. A Phase 2 combination study is ongoing.
Semaglutide (Novo Nordisk)#
Semaglutide 2.4 mg (Wegovy) is the first GLP-1 agonist approved specifically for weight management, achieving approximately 15% weight loss at 68 weeks. Novo Nordisk's combination approach pairs semaglutide with cagrilintide (CagriSema).
Comparison Table#
| Feature | Eloralintide | Cagrilintide | Tirzepatide | Semaglutide |
|---|---|---|---|---|
| Class | Selective amylin agonist | Non-selective amylin agonist | GLP-1/GIP agonist | GLP-1 agonist |
| Target | AMY1R (selective) | AMY1-3R + CTR | GLP-1R + GIPR | GLP-1R |
| Route | SC weekly | SC weekly | SC weekly | SC weekly |
| Peak weight loss | ~20% (48 wk, Ph2) | ~11.5% (68 wk, Ph3 mono) | ~22.5% (72 wk, Ph3) | ~15% (68 wk, Ph3) |
| GI tolerability | Favorable (selective) | Moderate (non-selective) | Moderate | Moderate |
| Body composition | Preferential fat loss (preclinical) | Not characterized | Under investigation | Under investigation |
| Developer | Eli Lilly | Novo Nordisk | Eli Lilly | Novo Nordisk |
| Status | Phase 3 | Phase 3 (CagriSema) | Approved | Approved |
Competitive Landscape#
The anti-obesity drug landscape is evolving rapidly. Eloralintide's competitive positioning rests on:
- Mechanistic differentiation: The only AMY1R-selective agonist, potentially offering a better tolerability-to-efficacy ratio than non-selective amylin analogs
- Combination potential: Designed to complement Lilly's existing tirzepatide franchise through amylin pathway activation
- Monotherapy efficacy: 20.1% weight loss approaches that of leading incretin therapies, offering an alternative for patients who do not tolerate or respond to GLP-1 agonists
- Body composition: Preclinical evidence of preferential fat loss could differentiate eloralintide if confirmed in human trials
Related Reading#
Frequently Asked Questions About Eloralintide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer